Ramaswamy raises nearly $10 million since entering Ohio gubernatorial race
Ramaswamy, who ran in the 2024 Republican Party presidential primary before dropping out last January, brought in $9.7 million since launching his gubernatorial run in late February, his campaign said in a release Tuesday.
'Raising this historic amount in just four months sends a powerful message: Ohioans are eager for bold, transformative leadership that will propel our state to new heights,' Ramaswamy's campaign manager, Jonathan Ewing, said in a statement.
'The remarkable surge of support in the final week of the quarter exceeded all expectations, proving that Vivek is uniting people across the state and is ready to usher in a new era of prosperity and opportunity for every Ohioan,' Ewing added.
Ramaswamy, a biotech entrepreneur, formally launched his run for Ohio governor Feb. 24. Prior to his campaign, Ramaswamy was chosen by President Trump late last year, alongside tech billionaire Elon Musk, to head the Department of Government Efficiency (DOGE).
Ramaswamy, a Trump ally, departed DOGE in January.
Ramaswamy, who is running to succeed outgoing Gov. Mike DeWine (R), was endorsed by both Trump and Musk, who have since clashed and recently reignited their feud.
Campaign fundraising records are set to be public July 30. Ramaswamy's campaign said it has hosted more than 50 fundraising events and accumulated more than 40,000 donors.
Apart from Ramaswamy, former Ohio health director Amy Acton is running in the race as a Democrat. Buckeye State Attorney General Dave Yost launched a bid for the seat but suspended his run in mid-May after the state Republican Party endorsed Ramaswamy.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
ACHV: Achieve's Busy Day
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30th. This is the culmination of more than a decade of work developing cytisinicline for smoking cessation. Now that the development phase of cytisinicline for smoking cessation is coming to a close, we look towards the regulatory and commercialization phases. We expect to see the FDA formally accept the NDA by late August and Achieve's management team to turn its attention towards the sales effort. Assuming normal turnaround times, we expect the FDA to set a target action date sometime in 2Q:26. NDA Submission Achieve announced its NDA submission of cytisinicline for smoking cessation in a June 26th press release. The company conducted two Phase III studies, an open label safety study and other studies that evaluated over 2,000 participants with the results demonstrating the safety, efficacy and tolerability of cytisinicline. We expect to see acceptance of the NDA within 60 days and further expect additional safety data from the ongoing ORCA-OL trial to be shared with the agency near year end. Commercialization Partnership Now that the new drug application has been submitted, Achieve is further advancing its commercialization efforts. During its earnings calls, the company has outlined its commercialization strategy and is now partnering with Omnicom Group to execute the plan. Omnicom Group provides brand and advertising services to thousands of clients globally and is one of the world's largest advertising and marketing services companies. Achieve will work with Omnicom subsidiary Credera, which is focused on digital transformation services. Credera combines consulting, artificial intelligence (AI) and technology expertise to build consumer technology platforms, integrate marketing technology systems and provide strategic consulting services. It will help Achieve to precisely target and engage healthcare professionals and patients through optimization of channel performance and acceleration of meaningful engagement. The team executing the initiative will include Goodby, Silverstein & Partners, DDB Health, and Ketchum Health which are health care-focused subsidiaries of the Omnicom marketing group. The various subsidiaries will provide expertise in consumer brand development, medical education and strategic public relations and communications, applying industry insights to support cytisinicline launch. In the Achieve partnership, Ketchum Health brings public relations and communications expertise, while Credera handles technology, Goodby Silverstein provides creative advertising, and DDB Health focuses on healthcare marketing. The partnership will use generative AI, predictive analytics and social listening to enhance targeting and personalization. Using a comprehensive approach, it will also employ healthcare applications, pharmacies and data providers to expand the reach and depth of insights. Omnicom has worked as media agency, digital and brand experience for other pharmaceutical and biotechnology clients including established firms such as AbbVie, AstraZeneca, Novartis and Moderna among others. Achieve will be the first small company that Omnicom has supported in commercializing a newly approved drug. Therefore, Omnicom will take on a broader strategic role than in its past partnerships. The Omnicom team will help communicate the optimal message to the provider and patient and monitor its effectiveness in real time. This will allow for rapid course corrections and focus on high value activities. Achieve has identified several target groups for its marketing efforts that are stratified by age, social media use and other demographic data. It was able to identify these groups based on subject experiences in the company's many clinical trials. We anticipate that the structure of Achieve's internal marketing team will be heavily tilted toward supporting the digital campaign with contract representatives available for in-person physician meetings when appropriate. Public Offering On June 30th, 2025 Achieve closed its $45 million capital raise. 15 million shares were issued at $3.00, each of which included an attached warrant exercisable at $3.00 per share. An additional 1,766,666 warrants were issued upon the partial exercise by the underwriters of their option to purchase additional shares, bringing total issued warrants to approximately 16.8 million. Net proceeds from the capital raise are estimated to be $41.3 million as disclosed in the June 27th Form 8-K filing. ORCA-OL Safety Trial Achieve began 2025 by announcing that 300 participants had completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial. The Data Safety Monitoring Committee (DSMC) identified no safety concerns as of this milestone allowing registrational filing with the FDA. As of May 2025, a third DSMC safety review was completed which also found no unexpected treatment-related adverse events. As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment. Furthermore, about 75% of the 479 (~360) individuals remained on treatment in the trial. We think that it is a material real-world positive that so many participants would remain on a smoking cessation product for that long a period suggesting that cytisinicline is well tolerated. This is particularly notable given the high discontinuation rates for Chantix and the associated unpleasant side effects such as nausea, headache, abnormal dreams and constipation.[1] Achieve expects to complete the one-year safety data package in the next few months and will submit this to the FDA by the 120-day safety review milestone. This should be around year-end 2025. Achieve expects that it will far exceed the 100-patient minimum required for one year of safety observations and could see as many as 300 patients with one year of exposure. Since one of the secondary endpoints is efficacy, this study should be able to show a wealth of data that can help providers use cytisinicline more effectively especially in chronic areas of disease such as Chronic Obstructive Pulmonary Disease (COPD) and cardiology. Milestones Development of cytisinicline product label for smoking cessation – 1H:25 Completion of six months of ORCA-OL safety data for 300 subjects – January 2025 Attendance at Oppenheimer Healthcare Life Sciences Conference, Virtual – February 2025 Attendance at Barclays Healthcare Conference, Miami – March 2025 Selection of 3rd party logistics partner – 2Q:25 NDA Submission – 2Q:25 FDA data submission from patients with twelve months of exposure to cytisinicline – 4Q:25 Launch of Phase III vaping trial – 1H:26 FDA target action date for cytisinicline NDA – 1H:26 Launch of cytisinicline – 3Q:26 SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer . ________________________ [1] Minian, N., et al. Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. BMC Public Health. March 2024.
Business Upturn
16 minutes ago
- Business Upturn
On Eve of Massive Spending Proposal, Resurfacing Presentation from Former Pentagon Advisor Suggests Untapped U.S. Asset Could Quietly Balance the Books
Washington, D.C., July 05, 2025 (GLOBE NEWSWIRE) — As President Trump prepares to introduce a sweeping legislative package—described by insiders as a 'Big Beautiful Bill' with trillion-dollar implications—a released presentation by former White House advisor Jim Rickards may offer a surprising counterbalance. According to Rickards, the U.S. already controls a little-known national asset capable of offsetting many of the bill's fiscal demands—without borrowing, taxing, or printing new dollars. 'The nature of this 'trust' as I call it, is such that politicians haven't been able to raid it… which has allowed it to grow untouched… for decades' . 'This is not some kind of government program like those COVID relief checks,' he adds. 'But it is a chance for the average American to become richer than they ever imagined' . A Resource Base Hidden in Plain Sight The presentation points to a vast store of natural resources—buried beneath federally owned land—stretching across the United States. These include copper, lithium, uranium, and other strategic minerals essential to infrastructure, defense, and energy systems. '$516 billion is here in the Salton Sea area of California… $3.1 trillion in Nome, Alaska. And $7.35 trillion in Midland, Texas…' . Rickards notes that these reserves have been known to government agencies for decades, but effectively off-limits due to environmental red tape and political inertia. 'For the past 50 years, fake-experts have strangled us from within the government,' he says. 'They tied us down with reams of regulation' . Trump's Pivot to Domestic Wealth With the introduction of this new bill—which some expect to prioritize military modernization, industrial revitalization, and energy security—Rickards believes the shift toward using domestic assets isn't just philosophical, it's practical. 'Trump is re-opening our mineral-rich Federal Lands. And fast-tracking companies that could recover trillions of dollars' worth of resources, right here in America'. 'There are certain areas where we have great, raw earth… and we're not allowed to use it because of the environment. I'm going to open them up,' Trump said . Decades of Delay. Days from Decision. The presentation references several high-value resource projects that have been stuck in limbo for years: 'Resolution Copper Mine… 29 years' 'Pebble Mine… since 1990' 'Thacker Pass Lithium Mine… since 1978' Now, Rickards says, the clock may finally be ticking in the other direction. 'We know exactly where these minerals are. We know they're worth trillions of dollars. And now—for the first time in half a century—we can go get them' . A New Path Forward? Rickards argues this isn't a question of what to create—but whether we'll finally use what's already ours. 'It's not earmarked for any specific individual,' he clarifies. 'I'm just trying to use terminology that will make the most sense to viewers' . 'We've had this rich endowment right under our feet… yet for years, we refused to touch it' . As Congress prepares for a new budget cycle, the presentation adds fuel to a growing conversation: Can America build the future… with what it already owns? About Jim Rickards Jim Rickards is a former advisor to the CIA, Pentagon, and U.S. Treasury. He played a key role in the Petrodollar Accord in the 1970s, has counseled the U.S. government through major financial and geopolitical events, and is the author of seven New York Times bestselling books. He now serves as a strategic analyst focused on national resilience, resource policy, and economic forecasting. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
16 minutes ago
- Business Upturn
PBK Miner Reports Strong Global Growth and Expands XRP Mining Contracts as Cloud Mining Demand Surges
London, UK, July 05, 2025 (GLOBE NEWSWIRE) — PBK Miner, a global cloud mining service provider headquartered in the United Kingdom, has announced continued growth and strong platform engagement across its user base of over 8.5 million global users. Building on its success in Bitcoin and multi-asset cloud mining, PBK Miner is expanding its XRP cloud mining contracts, offering flexible, low-risk entry points to digital asset mining with transparent returns and zero hardware requirements. The platform now supports mining for BTC, DOGE, ETH, XRP, LTC, SOL, USDT, and USDC, with users able to earn passive income directly from mobile devices or desktops, without the need for physical mining rigs or technical expertise. XRP Mining Contracts Drive Growth In response to rising user demand and consistent performance in its infrastructure, PBK Miner has significantly expanded its XRP cloud mining plans, which now account for a substantial portion of the platform's mining activity. According to internal performance data, XRP contract purchases grew 378% week-over-week, highlighting increased investor confidence in flexible, asset-specific mining options. Available XRP contracts include: $100 Plan – 2 days – Earn $3.50/day – 2 days – Earn $1,000 Plan – 9 days – Earn $13.50/day – 9 days – Earn $5,000 Plan – 30 days – Earn $77.50/day – 30 days – Earn $10,000 Plan – 45 days – Earn $165.00/day Each contract offers a guaranteed principal return at maturity, supported by PBK Miner's AI-optimized profit engine and global green-powered data centers. Zero-Risk Mining With Free Daily Contracts PBK Miner continues to democratize digital asset mining by offering all new users a free $10 daily cloud mining contract, which earns $0.60 every 24 hours—with no credit card, deposit, or hardware required. This zero-risk model allows users to experience real-world mining performance firsthand, making it an attractive gateway for beginners, students, and financially cautious investors. Key Metrics and Features Daily Free Contract : $10 trial contract earns $0.60/day : $10 trial contract earns $0.60/day Contract Terms : Range from 1 to 50 days, with investment levels from $10 to $100,000 : Range from 1 to 50 days, with investment levels from $10 to $100,000 Global Reach : Available in 183+ countries , supporting multiple languages : Available in , supporting multiple languages Secure Environment : Powered by Cloudflare and McAfee security standards : Powered by security standards Sustainable Mining : Uses renewable energy infrastructure across data centers : Uses renewable energy infrastructure across data centers No Maintenance Fees: 100% earnings transparency for all users Seamless and Mobile-Friendly Experience The PBK Miner interface is built for simplicity and speed, allowing anyone to begin mining in minutes: Visit or download the mobile app Register an account View and activate daily contracts Monitor earnings in real-time and scale up as desired Strategic Vision for 2025 and Beyond PBK Miner's roadmap includes continued diversification of supported digital assets, expansion into additional emerging markets, and deeper integration of machine learning models to optimize mining profitability and reduce operational emissions. The company's goal remains clear: to build a safe, transparent, and environmentally sustainable global mining ecosystem that is accessible to all, regardless of financial background or geography. 'Our platform is built for inclusivity,' said Alison Evans, PBK Miner spokesperson. 'We're removing technical and financial barriers and letting users experience real cloud mining in a secure, transparent environment—with complete control and zero risk.' About PBK Miner Founded in 2019, PBK Miner is a leading cloud mining and crypto asset management platform. With a growing global user base, PBK Miner is committed to providing a next-generation mining experience that is user-friendly, eco-conscious, and financially inclusive. Website: Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or a trading recommendation. Cryptocurrency mining and staking involve risks and may result in the loss of funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
